Novartis And Medicines For Malaria Venture Launch Coartem® Dispersible, The First ACT* Developed For Children Suffering From Malaria
Novartis and Medicines for Malaria Venture (MMV) announced the launch of Coartem® Dispersible, a new pediatric formulation of Coartem® (artemether/lumefantrine 20 mg/120 mg), for the treatment of uncomplicated malaria in infants and children.
More: continued here
Filed under: Pharma Industry on February 2nd, 2009
You must be logged in to post a comment.